Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

GlobeNewswire June 24, 2022

Daré Bioscience to Participate in the 2022 BIO International Convention

GlobeNewswire June 6, 2022

Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire May 16, 2022

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

GlobeNewswire May 12, 2022

Daré Bioscience Announces NIH Grant Award

GlobeNewswire May 11, 2022

Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022

GlobeNewswire May 5, 2022

Daré Bioscience to Participate in Upcoming Conference

GlobeNewswire April 14, 2022

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

GlobeNewswire April 12, 2022

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

GlobeNewswire March 31, 2022

Organon Enters into Global License Agreement to Commercialize Daré Bioscience's XACIATO(TM) (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

Business Wire March 31, 2022

Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022

GlobeNewswire March 24, 2022

Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

Daré Bioscience to Participate in Upcoming Conferences

GlobeNewswire March 2, 2022

Daré Bioscience to Participate in Upcoming Conferences

GlobeNewswire February 7, 2022

Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

GlobeNewswire January 4, 2022

Daré Announces FDA Approval of XACIATO(TM) (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

GlobeNewswire December 7, 2021

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

GlobeNewswire November 10, 2021

Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 9, 2021

Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021

GlobeNewswire November 3, 2021

Daré Bioscience to Participate in Panel Discussion at DTC Perspectives' Xpectives.Health Summit, October 12-14, 2021

GlobeNewswire October 6, 2021